U.S. health regulators pledged again Thursday to try to ban menthol cigarettes, this time under pressure from African American groups to remove the mint flavor popular among Black smokers.
The Food and Drug Administration has attempted several times to get rid of menthol but faced pushback from Big Tobacco, members of Congress and competing political interests in both the Obama and Trump administrations. Any menthol ban will take years to implement and will likely face legal challenges from tobacco companies.
Thursday’s announcement is the result of a lawsuit filed by anti-smoking and medical groups last summer to force the FDA to finally make a decision on menthol, alleging that regulators had “unreasonably delayed” responding to a 2013 petition seeking to ban the flavor.
The deadline for the agency’s response was Thursday. The FDA said it aims to propose regulations banning the flavor in the coming year.
The action would also ban menthol and fruity flavors from low-cost, small cigars, which are increasingly popular with young people, especially Black teens.
“We will save save hundreds of thousands of lives and prevent future generations from becoming addicted smokers,” said Dr. Janet Woodcock, the FDA's acting commissioner.
She cited research estimates that banning menthol would prevent 630,000 tobacco-related deaths over 40 years, more than a third of them among African Americans.
Menthol is the only cigarette flavor that was not banned under the 2009 law that gave the FDA authority over tobacco products, an exemption negotiated by industry lobbyists. The act did, though, instruct the agency to continue to weigh banning menthol.
The flavor’s persistence has infuriated anti-smoking advocates, who point to research that menthol’s numbing effect masks the harshness of smoking, likely making it easier to start and harder to quit.
The mint-flavored cigarettes are overwhelmingly used by young people and minorities, particularly Black smokers, 85% of whom smoke menthols. That compares to about a third of white smokers.
“The science is there, the data is there, so why are these products still on the market?” said Carol McGruder of the African American Tobacco Control Leadership Council.
Her group sued along with Action on Smoking and Health, the American Medical Association and the National Medical Association, which represents Black physicians.
For decades, companies focused menthol marketing and promotions on Black communities, including sponsoring music festivals and neighborhood events. Company documents released via 1990s litigation also show companies viewed menthol cigarettes as good “starter” products because they were more palatable for teenagers .
“There was a specific, intentional focus on creating the next generation of smokers by making menthol cigarettes available in those communities,” said Dr. Nia Heard-Garris, who chairs the American Academy of Pediatrics’ group on minority health and equity.
Soildus Labs, a market compliance and surveillance technology provider for crypto firms, has spearheaded the launch of the Crypto Market Integrity Coalition, a pledge committing to a safe and sensibly-regulated crypto industry. Kathy Kraninger, VP of Regulatory Affairs at Solidus Labs, discusses on Cheddar News' Closing Bell the biggest problems in the digital asset space that this new initiative plans to solve.
Stocks closed mixed Monday as a broader tech sell-off continued, leading the Nasdaq to close down 0.58%. Investors are keeping an eye on earnings, and also looking ahead to Thursday's CPI data, which will give an idea of how hot inflation could still be running. Steve Sosnick, Chief Strategist at Interactive Brokers, joins Closing Bell to discuss today's close, the Federal Reserve's plans to raise interest rates and taper asset purchasing, his 2022 market outlook, and more.
The global chip shortage continues to weigh on the automotive industry. For example, Ford says it is suspending or cutting production at eight of its factories in North America through next week due to the shortage. Balu Balakrishnan, President and CEO of Power Integrations, joins Cheddar News' Closing Bell, where he elaborates on why the chip shortage has dragged into 2022.
Peloton has weathered a seemingly never-ending storm the past few months: PR blunders, sinking customer demand, and in recent weeks, reported cost-cutting and potential layoffs. Now, several companies are said to be in the mix as potential buyers: Amazon, Netflix, Disney, and Apple. How likely is it that one of these companies pursues a deal — and how likely is it that it will be Apple who buys Peloton? Dan Ives, Managing Director of Equity Research at Wedbush Securities, joins Closing Bell to discuss his thoughts about Apple pursuing a Peloton takeover,
Astra aborted the launch for NASA ELaNa 41 Mission out of Cape Canaveral on Monday due to what was described as a minor issue, but the company's stock fell nearly 14 percent following the news. Jim Cantrell, CEO and co-founder of Phantom Space, which builds and launches spacecraft of its own, joined Cheddar to discuss the scrubbed mission. “The last thing you want is for this to go wrong, you're better to err on the side of safety expectations,” Cantrell explained, noting that the mission delay was a normal event.
Dating app Bumble announced its first acquisition, expanding into Europe by picking up Fruitz, a French Platform. The Fruitz app allows its users to convey dating preferences through fruit metaphors.
Meat production giant Tyson Foods reported a beat on its Q1 earnings. In spite of obstacles posed by supply chain issues and inflation, the company exceeded expectations on earnings per share and revenue.
TC BioPharm, a biopharmaceutical company focused on developing cell therapy products targeting, went public on the Nasdaq in January. CEO Bryan Kobel joined Cheddar to talk about the company's IPO launch, its cancer-fighting therapeutics tech, and its potential for using its research to treat COVID-19. "The opportunity here for us is to really get safety data and covid and expand into other areas," Kobel said. "So from COVID, where we hope to treat patients, hopefully maybe the elderly population, populations that that really can't handle the antivirals because they're too hard in the system, well then we'll expand out into maybe severe influenza Ebola, other viral and viral infections where we think we can be helpful."
